FDA panel backs Roche's HPV assay as first-line cervical cancer screen
This article was originally published in Clinica
The US FDA’s Microbiology Devices Panel has unanimously backed Roche’s cobas HPV test to be marketed as a first-line cervical cancer screening test, meaning it could replace the current standard, Pap smear testing. But, assuming FDA follows the panel’s recommendations, national clinical guidelines will likely need to catch up as well. The US Preventative Services Task Force does not currently recommend first-line cervical cancer screening with HPV assays. It also “recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years.” The panel voted 13-0 that Roche’s assay was safe, effective and the benefits outweighed the risks. The test is already CE marked in Europe for first-line screening. In the US, HPV tests are only approved for use in conjunction with Pap.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.